Valuation: Positron Corporation

Market Cap 60.5M 53.09M 50.14M 45.69M 85.54M 5.8B 86.15M 600M 232M 2.96B 227M 222M 9.52B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 59.37M 52.09M 49.2M 44.84M 83.93M 5.69B 84.53M 589M 228M 2.91B 223M 218M 9.34B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%+74.47% - - 60.5M
+0.21%+1.40%-31.15%-2.47% 12.47B
-7.14%-2.36%+4.88%+6.07% 4.16B
-2.48%+1.37%-45.08%-60.64% 1.21B
-0.57%+3.04%-40.46%-43.14% 1.09B
+0.66%+4.43%+25.11%+98.15% 1.1B
-1.58%+1.70%-34.60% - 1.03B
-3.18%-0.52% - - 996M
-2.64%-4.46%+29.12%+93.38% 494M
+7.78%-0.75%+46.15% - 333M
Average -0.64%+0.43%-5.76%+15.23% 2.54B
Weighted average by Cap. -1.45%+0.71%-20.35%+1.35%

Financials

2024 2025
Net sales 588K 516K 487K 444K 831K 56.31M 837K 5.83M 2.26M 28.77M 2.21M 2.16M 92.45M 461K 405K 382K 349K 652K 44.23M 657K 4.58M 1.77M 22.59M 1.73M 1.7M 72.62M
Net income -2.38M -2.09M -1.97M -1.8M -3.36M -228M -3.39M -23.59M -9.14M -116M -8.93M -8.74M -374M -10.6M -9.3M -8.79M -8.01M -14.99M -1.02B -15.1M -105M -40.73M -519M -39.81M -38.95M -1.67B
Net Debt 1.42M 1.25M 1.18M 1.08M 2.01M 137M 2.03M 14.13M 5.47M 69.75M 5.35M 5.23M 224M -1.14M -997K -942K -858K -1.61M -109M -1.62M -11.27M -4.36M -55.63M -4.27M -4.17M -179M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-